Pharmaceutical Corruption Media Articles

Excerpts of Key Pharmaceutical Corruption Media Articles in Major Media

Below are key excerpts of revealing news articles on pharmaceutical industry corruption from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

For further exploration, delve into our comprehensive Health and Food Corruption Information Center.

Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.

DREW GRIFFIN, CNN INVESTIGATIVE CORRESPONDENT: Pfizer, Incorporated, with 116,000 employees and revenues of $50 billion a year, is the world's largest pharmaceutical company. The government was building a case against Pfizer for fraudulently marketing a drug that had raked in hundreds of millions of dollars in profits, a painkiller called Bextra. Pfizer aggressively marketed it for uses and in doses not approved by the FDA. But our investigation found another story, ... about the power major pharmaceutical companies have, even when they break the laws intended to protect patients. In 2001, ... the FDA approved Bextra, but only for limited use and only for menstrual cramps and arthritis. Even so, Pfizer sales reps promoted it, illegally, for surgical pain in higher doses, uses the FDA had rejected due to safety concerns. Doctors responded. Instead of prescribing, say, ibuprofen at pennies a pill, they prescribed Bextra at nearly $3 a pill for all kinds of unapproved uses. Sales were very good. GLENN DEMOTT, FORMER PFIZER SALES REP: They said that the district manager approved it. They think it might not be legal, but if they don't make their numbers, they're not going to keep their job anyway. GRIFFIN : It brought Pfizer nearly $1 billion in profits. And it cost us all, because Medicare, Medicaid, and our private insurance picked up much of the tab. MICHAEL LOUCKS, FORMER FEDERAL PROSECUTOR: If the company is able to push the product for the unapproved indication, then it makes a mockery, if you will, of the FDA approval process.

Note: For an even deeper analysis on Mercola.com titled "Pulling Back the Curtain on the Organized Crime Ring That Is the Pharmaceutical Drug Cartel," click here. You can also watch a video of the above CNN segment at that link. For more on pharmaceutical industry corruption, see the deeply revealing reports from reliable major media sources available here.

Most pharmaceutical companies have sworn off ghostwriting, the practice of writing "research" papers for doctors and then paying them to add their names as authors even when they had little involvement or the results were trivial. Merck (MRK), Forest Labs (FRX), and GlaxoSmithKline (GSK) have all been caught doing it. But what happens to the articles that have been disavowed by companies or discredited by lawyers? Not much, it turns out. They sit inside prestigious online archives of academic material, unretracted, where they look just like real studies with robust results. Ghostwriting doesn't look good in lawsuits, either. Pfizer (PFE) must now pay $9.5 million to a woman who claimed menopause drug Prempro gave her breast cancer; Wyeth - the company that made the drug and was later acquired by Pfizer - commissioned ghostwritten articles about the drug. So it's interesting to note that many of those pay-for-play articles are still sitting in scholarly archives such as PubMed, notching up bibliography references and footnotes, even though they shouldn't be. You can search for more ghostwritten papers here.

Note: Big Pharma giant Merck created a fake medical journal and created a list of doctors to discredit in order to popularize a dangerous drug that may have killed as many as 500,000 people before it was finally recalled. For more along these lines, see concise summaries of deeply revealing pharmaceutical corruption news articles from reliable major media sources.

Drug companies manipulated the World Health Organisation into downgrading its definition of a pandemic so they could cash in on a swine flu outbreak, it is claimed. An inquiry heard yesterday that the WHO allegedly softened its criteria for declaring a H1N1 flu pandemic last spring - just weeks before announcing there was a worldwide outbreak. Critics said the decision was driven by pharmaceutical companies desperate to recoup the billions of pounds they had invested in researching and developing pandemic vaccines after the bird flu scares in 2006 and 2007. As a result, millions of people have been vaccinated against a mild illness, and money that could have been used to prevent and treat major killers such as heart disease has been squandered. The claims, which emerged during the first of several Council of Europe hearings into the handling of the swine flu pandemic, were strongly rejected by the WHO. Following the organisation's declaration of a pandemic, the Department of Health warned of 65,000 deaths, set up a special advice line and website, and suspended normal rules so anti-flu drugs could be given without prescription. But with just 250 or so deaths in Britain and 14,000 worldwide, the WHO is being asked to account for its actions.

Note: For lots more on the swine flu "false pandemic" from reliable sources, click here.

Remember the warnings of 65,000 dead? Health chiefs should admit they were wrong – yet again – about a global pandemic. Let me recap. Six months ago [the] BBC was intoning nightly statistics on what "could" happen as "the deadly virus" took hold. The happy-go-lucky virologist, John Oxford, said half the population could be infected, and that his lowest estimate was 6,000 dead. The chief medical officer, Sir Liam Donaldson, bandied about any figure that came into his head, settling on "65,000 could die", peaking at 350 corpses a day. The media went berserk. The World Health Organisation declared a "six-level alert" so as to "prepare the world for an imminent attack". If anyone dared question this drivel, they were dismissed by Donaldson as "extremists". When people started reporting swine flu to be even milder than ordinary flu, he accused them of complacency and told them to "wait for next winter". He was already buying 32m masks and spending more than Ł1bn on Tamiflu and vaccines. It was pure, systematic government-induced panic – in which I accept that the media played its joyful part.

Note: For lots more on the gross profiteering and fear mongering of swine flu scare, click here.

More than half the scientists on the swine flu taskforce advising the [UK] Government have ties to drug companies. Eleven of the 20 members of the Scientific Advisory Group for Emergencies (SAGE) have done work for the pharmaceutical industry or are linked to it through their universities. Many have declared interests in GlaxoSmithKline, the vaccine maker expected to be the biggest beneficiary of the pandemic. The disclosure of the register of interests comes just days after a health expert branded the swine flu outbreak a 'false pandemic' driven by the drug companies which stood to profit. The Government is now trying to offload up to Ł1billion worth of unwanted swine flu vaccine. Last July, the Department of Health warned of up 65,000 deaths, with 350 a day at the pandemic's peak. But the death toll now stands at just 251. SAGE was created to give Ministers recommendations on how to control and treat the virus. Official documents show some members are linked to vaccine manufacturer Baxter and to Roche, which makes Tamiflu. GSK, Baxter and Roche stand to make up to Ł1.5billion between them from Government contracts related to swine flu.

Note: For lots more on the Swine Flu "false pandemic," click here.

Antidepressants ... may be no better than dummy pills for people with mild or moderate depression, according to a study that suggests 70 percent of patients wouldn’t benefit from the drugs. In a review of six trials of antidepressants involving more than 700 patients published yesterday in the Journal of the American Medical Association, researchers led by Jay Fournier at the University of Pennsylvania found the drugs helped only those patients with the most severe depression. Doctors, policy makers and sufferers should be made aware that there’s little evidence to show the treatments will benefit patients with less severe symptoms, the authors said. “This important feature of the evidence base is not reflected in the implicit messages present in the marketing of these medications to clinicians and the public,” they said. The researchers combined data from six trials. The drugs had a “nonexistent to negligible” effect on patients with mild, moderate and severe symptoms, compared with those who took a placebo, according to a commonly used scale used to measure the disorder. The pills had a large effect on patients with very severe symptoms, the study found.

Note: For a treasure trove of important reports on corruption regarding major health issues, click here.

The massive U.S. Senate healthcare reform measure passed ... with support from the multibillion drug industry, but makers of cheaper generic rivals are feeling left out in the cold. Generic drugmakers face several obstacles in the bill backed by Democrats that they worry will dampen a potential increase in use even as more people gain access to health insurance and prescription medicines. The hurdles include extensive protections against generic versions of pricey biotech medicines, an incentive for Medicare recipients to use more brand-name drugs, and a possible end to payments from brandname makers to delay the launch of copy-cat medicines. "The bill passed by the Senate unfortunately amounts to a treasure trove to brand drug companies," said Generic Pharmaceutical Association President Kathleen Jaeger. Bill Marth, chief executive of Teva's North American operations, said Democrats missed a chance to further boost [generics] use: "It's frustrating," he said. "Maybe some people have just lost sight of what the bill is supposed to do."

Note: For a powerful analysis by Dr. Marcia Angell, former editor in chief of the New England Journal of Medicine, of the corrupt relationship between the biggest pharmaceutical companies and the federal government, click here. Drug company lobbyists who contribute millions of dollars to the elections campaigns of Congress members have a huge influence which is often detrimental to public health.

Dr. Julie Gerberding, former director of the U.S. Centers for Disease Control and Prevention, was named president of Merck & Co Inc's vaccine division. Gerberding, who led the CDC from 2002 to 2009 and stepped down when President Barack Obama took office, will head up the company's $5 billion global vaccine business that includes shots to prevent chickenpox, cervical cancer and pneumonia. She had led CDC from one crisis to another, including the investigation into the anthrax attacks that killed five people in 2001, the H5N1 avian influenza, the global outbreak of severe acute respiratory syndrome, or SARS, and various outbreaks of food poisoning. She may be charged with reigniting flagging sales of Merck's Gardasil vaccine to prevent cervical cancer by protecting against human papillomavirus or HPV. After an encouraging launch Gardasil sales have been falling and were down 22 percent in the third quarter at $311 million.

Note: So the head of the CDC now is in charge of vaccines at one of the biggest pharmaceutical companies in the world. Could this be considered conflict of interest? Could this possibly be payback for supporting the vaccine agenda so strongly for years? For more on the risks and dangers of vaccines, click here.

A new report finds that the Centers for Disease Control and Prevention did a poor job of screening medical experts for financial conflicts when it hired them to advise the agency on vaccine safety. Most of the experts who served on advisory panels in 2007 to evaluate vaccines for flu and cervical cancer had potential conflicts that were never resolved, the report said. Some were legally barred from considering the issues but did so anyway. In the report ... Daniel R. Levinson, the inspector general of the Department of Health and Human Services, found that the centers failed nearly every time to ensure that the experts adequately filled out forms confirming they were not being paid by companies with an interest in their decisions. The report found that 64 percent of the advisers had potential conflicts of interest that were never identified or were left unresolved by the centers. Thirteen percent failed to have an appropriate conflicts form on file at the agency at all, which should have barred their participation in the meetings entirely, Mr. Levinson found. And 3 percent voted on matters that ethics officers had already barred them from considering.

Note: For lots more on corporate and government corruption from reliable sources, click here and here.

New federally financed drug research reveals a stark disparity: children covered by Medicaid are given powerful antipsychotic medicines at a rate four times higher than children whose parents have private insurance. And the Medicaid children are more likely to receive the drugs for less severe conditions than their middle-class counterparts, the data shows. Those findings, by a team from Rutgers and Columbia, are almost certain to add fuel to a long-running debate. Do too many children from poor families receive powerful psychiatric drugs not because they actually need them – but because it is deemed the most efficient and cost-effective way to control problems that may be handled much differently for middle-class children? The questions go beyond the psychological impact on Medicaid children, serious as that may be. Antipsychotic drugs can also have severe physical side effects, causing drastic weight gain and metabolic changes resulting in lifelong physical problems. Part of the reason is insurance reimbursements, as Medicaid often pays much less for counseling and therapy than private insurers do. Studies have found that children in low-income families may have a higher rate of mental health problems – perhaps two to one – compared with children in better-off families. But that still does not explain the four-to-one disparity in prescribing antipsychotics.

Note: For many important health reports from reliable sources, click here.

Drug company GlaxoSmithKline has told Canadian doctors to stop using one lot of its H1N1 vaccine until an investigation into a higher-than-expected number of severe allergic reactions is completed. The U.S. vaccine will not be identical to Arepanrix, the GSK H1N1 vaccine used in Canada. Arepanrix contains an adjuvant, a substance designed to boost the immune response, but adjuvants have never been approved for use in U.S. flu vaccines. Almost all of the 172,000 doses in question, distributed the week of Nov. 2 to six Canadian provinces, already have been administered, said Geoffrey Matthews, a spokeswoman for the Public Health Agency of Canada, which, with GSK and Health Canada, is investigating cases of anaphylaxis. Symptoms of anaphylaxis include trouble breathing, chest tightness and swelling of the mouth and throat. Six cases have been reported, Matthews says. In the USA, the Vaccine Adverse Event Reporting System said that as of Nov. 13 it had received 116 reports of serious health events related to the vaccine, including eight deaths – similar to the number in previous years after a similar number of seasonal flu vaccine doses had been shipped.

Note: For lots more on the risks of swine flu vaccines, click here.

Even as drug makers promise to support Washington's health care overhaul by shaving $8 billion a year off the nation's drug costs after the legislation takes effect, the industry has been raising its prices at the fastest rate in years. In the last year, the industry has raised the wholesale prices of brand-name prescription drugs by about 9 percent, according to industry analysts. That will add more than $10 billion to the nation's drug bill, which is on track to exceed $300 billion this year. By at least one analysis, it is the highest annual rate of inflation for drug prices since 1992. The drug trend is distinctly at odds with the direction of the Consumer Price Index, which has fallen by 1.3 percent in the last year. Critics say the industry is trying to establish a higher price base before Congress passes legislation that tries to curb drug spending in coming years. "When we have major legislation anticipated, we see a run-up in price increases," says Stephen W. Schondelmeyer, a professor of pharmaceutical economics at the University of Minnesota. A Harvard health economist, Joseph P. Newhouse, said he found a similar pattern of unusual price increases after Congress added drug benefits to Medicare a few years ago, giving tens of millions of older Americans federally subsidized drug insurance. Just as the program was taking effect in 2006, the drug industry raised prices by the widest margin in a half-dozen years. "They try to maximize their profits," Mr. Newhouse said.

Note: For lots more from reliable sources on corporate corruption, click here.

A $112 million settlement involving alleged drug kickbacks that the Justice Dept. announced with the nation's largest nursing home pharmacy and a generic drug manufacturer on Nov. 3 is part of a wide-ranging investigation of suspected Medicaid fraud by the pharmaceutical industry. Critics say the continuing probe, which involves ... major drugmakers, highlights what they describe as an industry practice of paying money to outfits that provide drugs to consumers, in return for preferential treatment. Because those alleged payoffs have the effect of compromising patient care and driving up costs for government and private health insurers, cases like the settlement unsealed with Omnicare (OCR) in Covington, Ky., and IVAX Pharmaceuticals in Weston, Fla., could bolster opposition to the controversial deal the Obama Administration reached with the pharmaceutical industry to win its support for health-reform legislation. Many Democrats say the Administration should have asked for much bigger cost savings from drugmakers. Patrick Burns, a spokesman for Taxpayers Against Fraud, a nonprofit Washington group that promotes whistleblower suits, says the Justice Dept. is backed up with pharmaceutical fraud cases. Since drugmakers offer so many similar products, he contends, they rely on kickbacks to give their products a market edge. "In the pharmaceutical industry, the business isn't selling the best drug, it's the best scheme of kickbacks to the prescriber."

Note: For lots more from reliable sources on corporate corruption, click here.

Swiss drugmaker Novartis said sales would grow faster than expected this year, even without a shot in the arm of up to $700 million from its H1N1 swine flu pandemic vaccine. Third-quarter net profit at Novartis ... nudged up 1 percent to $2.1 billion. This year is turning out to be better than initially feared for Novartis and other major pharmaceutical companies, thanks to hefty price increases and windfall sales arising from the H1N1 outbreak. Both Pfizer, the world's biggest drugmaker, and Eli Lilly topped earnings forecasts this week. Roche reported a sharp jump in sales of its Tamiflu drug for flu last week and analysts expect GlaxoSmithKline's Relenza will also see strong sales in the third quarter. On the vaccine front, Glaxo, Sanofi-Aventis and AstraZeneca are all expected to highlight an expected jump in fourth-quarter sales due to swine flu. The H1N1 flu vaccine is expected to contribute about $400-700 million of sales in the fourth quarter.

Note: Donald Rumsfeld personally made millions as a direct result of the avian flu scare a few year ago. For more on this, click here. For more on pharmaceutical corporation profiteering from swine flu vaccines, click here.

Did you know that Lunesta will help you fall asleep just 15 minutes faster? Or that a higher dose of the osteoporosis drug Zometa could damage a cancer patient’s kidneys and raise their risk of death? Chances are you didn’t, and neither did your doctor. Much of what the Food and Drug Administration knows about a drug’s safety and effectiveness is not included on the label, say two drug safety experts who are calling on the agency to make that information more accessible. In ... the New England Journal of Medicine, researchers ... argue that drug labels don’t reflect the nuanced decisions the FDA makes when deciding to approve a drug. The editorial from Drs. Lisa Schwartz and Steven Woloshin recommends easy-to-read fact boxes to help patients weigh the benefits and risks of medications. If drug labels sometimes exaggerate benefits and play down drug risks, the authors say there’s a very good reason: they are written by drugmakers. While FDA must approve the final labeling, the actual language is drafted by the manufacturer, with input from FDA scientists. The labeling is based on results from company studies, which generally compare results for patients taking the drug versus those taking placebo. If FDA decides the drug’s ability to treat or prevent a disease outweighs its side effects, the agency is obligated to approve it. But Schwartz and Woloshin point out that benefits may be slim and potential harms may not be fully understood. “The take home point is that just because a drug is approved doesn’t mean it works very well,” said Schwartz, in an interview with the Associated Press. “You really need to know more to see whether it’s worth the cost.” Schwartz and Woloshin say FDA labeling frequently fails to provide a full picture of a drug’s effects.

Note: For a powerful summary of corruption in the pharmaceutical industry, click here.

Americans are still debating whether to roll up their sleeves for a swine flu shot, but companies have already figured it out: vaccines are good for business. Drug companies have sold $1.5 billion worth of swine flu shots, in addition to the $1 billion for seasonal flu they booked earlier this year. These inoculations are part of a much wider and rapidly growing $20 billion global vaccine market. "The vaccine market is booming," says Bruce Carlson, spokesperson at market research firm Kalorama, which publishes an annual survey of the vaccine industry. "It's an enormous growth area for pharmaceuticals at a time when other areas are not doing so well," he says. As always with pandemic flus, taxpayers are footing the $1.5 billion check for the 250 million swine flu vaccines that the government has ordered so far and will be distributing free to doctors, pharmacies and schools. In addition, Congress has set aside more than $10 billion this year to research flu viruses, monitor H1N1's progress and educate the public about prevention. Drugmakers pocket most of the revenues from flu sales. But some say it's not just drugmakers who stand to benefit. Doctors collect copayments for special office visits to inject shots, and there have been assertions that these doctors actually profit handsomely from these vaccinations. Pharmacies also charge co-payments or full price of about $25 to those without insurance.

Note: For a revealing article questioning the efficacy of vaccines, click here. And for a powerful CBS '60 Minutes' news clip clearly showing how the profit motive in vaccines endangers public health, click here.

The pharmaceutical giant Pfizer agreed to pay $2.3 billion to settle civil and criminal allegations that it had illegally marketed its painkiller Bextra, which has been withdrawn. It was the largest health care fraud settlement and the largest criminal fine of any kind ever. The settlement had been expected. Pfizer, which is acquiring a rival, Wyeth, reported in January that it had taken a $2.3 billion charge to resolve claims involving Bextra and other drugs. It was Pfizer’s fourth settlement over illegal marketing activities since 2002. The government charged that executives and sales representatives throughout Pfizer’s ranks planned and executed schemes to illegally market not only Bextra but also Geodon, an antipsychotic; Zyvox, an antibiotic; and Lyrica, which treats nerve pain. While the government said the fine was a record sum, the $2.3 billion fine amounts to less than three weeks of Pfizer’s sales. Much of the activities cited Wednesday occurred while Pfizer was in the midst of resolving allegations that it illegally marketed Neurontin, an epilepsy drug for which the company in 2004 paid a $430 million fine and signed a corporate integrity agreement — a companywide promise to behave. John Kopchinski, a former Pfizer sales representative whose complaint helped prompt the government’s Bextra case, said that company managers told him and others to dismiss concerns about the Neurontin case while pushing them to undertake similar illegal efforts on behalf of Bextra. “The whole culture of Pfizer is driven by sales, and if you didn’t sell drugs illegally, you were not seen as a team player,” said Mr. Kopchinski.

Note: For lots more on corporate corruption, click here. For a powerful article on the immense political power of pharmaceutical companies by one of the top MDs in the U.S., click here.

Billionaire Mayor Michael Bloomberg defended multibillion-dollar pharmaceutical companies and their chief executives on Friday, declaring that they "don't make a lot of money" and shouldn't be scapegoats in the health care debate. The mayor — and wealthiest person in New York City with a fortune estimated at $16.5 billion — made the comments on his radio show Friday. "You know, last time I checked, pharmaceutical companies don't make a lot of money, their executives don't make a lot of money," Bloomberg said. Pharmaceutical CEOs are known to make millions, with generous salaries, stock options and other perks. Abbott Laboratories Inc. Chairman and Chief Executive Miles White's compensation was $25.3 million in 2008. The North Chicago, Ill.-based company saw profit rising 35 percent to $4.88 billion. Merck & Co.'s chief executive, Richard T. Clark, received a $17.3 million compensation package for 2008. The company's profit more than doubled to $7.8 billion. The mayor ... often battles criticism that he is out of touch with regular people. Earlier this year he declared "we love the rich people" while arguing against raising taxes on the wealthy. It was clear that Bloomberg or one of his aides realized his gaffe while he was still on the air Friday. The mayor, who has sought to cast himself as a financial and business expert, came back from a break and said he had looked up the pay of some pharmaceutical executives. "Some of them are making a decent amount, more than a decent amount of money," he said.

Amid questions about the safety of the HPV vaccine Gardasil, one of the lead researchers for the Merck drug is speaking out about its risks, benefits and aggressive marketing. Dr. Diane Harper says young girls and their parents should receive more complete warnings before receiving the vaccine to prevent cervical cancer. Dr. Harper helped design and carry out the Phase II and Phase III safety and effectiveness studies to get Gardasil approved, and authored many of the published, scholarly papers about it. She has been a paid speaker and consultant to Merck. It's highly unusual for a researcher to publicly criticize a medicine or vaccine she helped get approved. Dr. Harper joins a number of consumer watchdogs, vaccine safety advocates, and parents who question the vaccine's risk-versus-benefit profile. She says data available for Gardasil shows that ... there is no data showing that it remains effective beyond five years. This raises questions about the CDC's recommendation that the series of shots be given to girls as young as 11-years old. "If we vaccinate 11 year olds and the protection doesn't last... we've put them at harm from side effects, small but real, for no benefit," says Dr. Harper. "The benefit to public health is nothing, there is no reduction in cervical cancers, they are just postponed, unless the protection lasts for at least 15 years, and over 70% of all sexually active females of all ages are vaccinated." She also says that enough serious side effects have been reported after Gardasil use that the vaccine could prove riskier than the cervical cancer it purports to prevent. Cervical cancer is usually entirely curable when detected early through normal Pap screenings.

Note: For more on the dangers of vaccines, see the deeply revealing reports from reliable major media sources available here.

The time, money and manpower that lobbying firms devote to courting lawmakers reveals an investment inside the Beltway of staggering proportions. For every lawmaker in Congress, there are about six lobbyists pushing their health care priorities, according to a Bloomberg News investigation released today. That's about 3,300 registered health care lobbyists working Capitol Hill. A total of $263 million has been spent on health lobbying in 2009, according to the latest data from the Center for Responsive Politics. That's more money spent on health than any other sector this year. The list of the top 20 spenders in 2009 across all sectors includes the U.S. Chamber of Commerce at No. 1, spending more than $26 million, Pharmaceutical Research and Manufacturers of America (PhRMA) at No. 3, spending $13 million, and Pfizer in the No. 6 spot, spending $11 million. Also joining the ranks of the top 20 spenders this year are Blue Cross Blue Shield, AARP, American Hospital Association, American Medical Association and Eli Lilly, each having doled out between $7 and $10 million this year. Wendell Potter, a 20-year health insurance veteran and former CIGNA vice president, ... spoke out about insurance companies operating behind the scenes. Potter recalled previous health care fights, saying insurers have undoubtedly tried to shape the battle. "It is usually done through the PR firms that work for them," Potter said. "They want to keep their fingerprints off stuff like that. "With this history, you can rest assured that the industry is up to the same dirty tricks, using the same devious PR practices it has used for many years to kill reform this year, or even better, to shape it so that it benefits insurance companies and their Wall Street investors far more than average Americans," he said.

Note: For lots more on the corrupt medical/governmental complex, click here.

Important Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.